Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Endothelial Dysfunction
100%
Diabetes
100%
Poly(ADP-ribose) Polymerase
100%
Myocardial Dysfunction
100%
Cardiac Dysfunction
50%
Beneficial Effects
33%
PARP Inhibitor (PARPi)
33%
Streptozotocin-induced
33%
High Incidence
16%
Vascular Reactivity
16%
Hyperglycemia
16%
Diabetic
16%
Vascular Complications
16%
Thoracic Aorta
16%
Neuropathy
16%
Myocardial Infarction
16%
Nephropathy
16%
Retinopathy
16%
Endothelium-dependent Vasodilation
16%
Poly (ADP-ribose) Polymerase Inhibition
16%
Diabetic Cardiomyopathy
16%
Severe Hyperglycemia
16%
PJ34
16%
Patients with Diabetes
16%
Cardiovascular Complications
16%
Diabetic Model
16%
Non-obese Diabetic
16%
Hypertension Risk
16%
Diastolic Dysfunction
16%
Induced Models
16%
Pharmacology, Toxicology and Pharmaceutical Science
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase
100%
Endothelial Dysfunction
100%
Hyperglycemia
33%
Streptozotocin
33%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
33%
Diabetes Mellitus
16%
Kidney Disease
16%
Neuropathy
16%
Heart Infarction
16%
Retinopathy
16%
Diabetic Cardiomyopathy
16%
N (5,6 Dihydro 6 Oxo 2 Phenanthridinyl) 2 Dimethylaminoacetamide
16%
Diastolic Dysfunction
16%
Cerebrovascular Accident
16%
Cardiovascular Disease
16%